09:52am Thursday 16 August 2018

A protein could be key to preserving heart function in Duchenne muscular dystrophy

Study Highlights:

  • The brain-derived neurotrophic factor protein, known to be vital for brain function, might hold the key for preserving heart function in children and young adults with Duchenne muscular dystrophy.
  • Heart failure often kills Duchenne patients early in life and there is no effective treatment.
  • Developing therapies designed to activate or supplement brain-derived neurotrophic factor could give new hope to patients at risk for Duchenne cardiomyopathy.

 

SAN ANTONIO, TEXAS  — A protein known to drive nerve cell survival in the brain and spinal cord might also protect failing hearts in children and young adults with Duchenne muscular dystrophy, according to preliminary research presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions, a premier global exchange of the latest advances in basic cardiovascular science.

Children with Duchenne muscular dystrophy often begin to lose muscle strength and function between ages three and five. Duchenne cardiomyopathy follows, in which patients’ heart muscles stiffen and lose function. Cardiomyopathy often leads to heart failure and death in children and young adults with the disease.

It’s hard to predict when cardiomyopathy will happen in Duchenne patients, but when it does, there are no effective or specific treatments aimed at preserving heart function at this time, according to study author Cristi L. Galindo, Ph.D., M.B.A., research assistant professor of medicine at Vanderbilt University Medical Center in Tennessee. Gaining a greater understanding of how cardiomyopathy occurs in these patients could help to develop future treatment.

Galindo and colleagues studied a small group of Duchenne muscular dystrophy patients and measured blood levels of the protein brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin kinase B (TrKB). The receptor, TrKB, attaches to BDNF which then sends chemical signals to the cells to protect against cell death. They noted that BDNF seemed to increase initially in patients whose hearts were still functioning but decreased as patients’ heart function declined.

“Researchers have long known that BDNF is important for brain function. It helps brain cell survival and growth and promotes memory. Our research shows BDNF also appears to be heart protective and heart specific. Data suggests the more there is, the better the heart function in the patient,” Galindo said.

In addition, researchers examined whether it was possible to increase BDNF and if it might preserve heart function in these patients by studying mice that mimicked human Duchenne patients’ disease progression.

The researchers gave mice a plant-derived compound, the TrkB agonist 7,8-dihydroxyflavone (DHF), that binds to the TrkB receptor, mimicking the cell-preserving activity that occurs when BDNF binds to the receptor. The compound was administered orally for 26 weeks in the mice’s drinking water.

“The fact that DHF can be delivered orally is important for Duchenne patients,” she said. “These children are suffering from muscle degeneration. You don’t want to poke them every five minutes.”

Echocardiography showed DHF preserved the heart’s function, compared to mice that didn’t receive DHF. When researchers gave mice the TrkB inhibitor K252a, the opposite occurred and heart function declined.

In general, Galindo and colleagues found BDNF and TrkB are required for the heart’s strong and vigorous contraction (contractility) and survival of cardiomyocytes – the heart’s cells.

If the research about using DHF as treatment pans out in humans, BDNF therapy that supplements or activates BDNF signaling could be a new way to treat Duchenne cardiomyopathy. The next steps, according to Galindo, are to test more potent compounds in larger animals.

Co-authors are Cassandra P. Awgulewitsch, B.S.; Jonathan H. Soslow, M.D.; Lin Zhong, M.D., Ph.D.; Erica J. Carrier, Ph.D.; Anand P. Singh, Ph.D.; Prachi Umbarkar, Ph.D.; Qinkun Zhang, M.D.; Frank Raucci, M.D., Ph.D.; Larry W. Markham, M.D.; Hind Lal, Ph.D.; and Antonis K. Hatzopoulos, Ph.D.

This study did not receive outside funding. Author disclosures are on the abstract.

 

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

###

AThe American Heart Association

 

 


Share on:
or:

MORE FROM Bones and Muscles

Health news